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When glioblastoma multiforme (GBM) is treated with anti-vascular endothelial growth factor (VEGF) 
agents, it commonly exhibits tumor progression due to the development of resistance, which results 
in a dismal survival rate. GBM tumors contain a large number of monocytes/macrophages, which have 
been shown to be resistant to the effects of bevacizumab. It has been reported that tumor-associated 
macrophages (TAMs) promote resistance to bevacizumab treatment. Therefore, it is important to 
target TAMs in the GBM microenvironment. TAMs, which depend on chemokine ligand 2 (CCL2) for 
differentiation and survival, induce the expression of proangiogenic factors such as VEGF. Dynamic 
susceptibility contrast (DSC)-MR imaging is an advanced technique that provides information on tumor 
blood volume and can potentially predict the response to several treatments, including anti-angiogenic 
agents such as bevacizumab, in human GBM. In this study, we used a CCL2 inhibitor, mNOX-E36, to 
suppress the recruitment of TAMs in a CCL2-expressing rat GBM model and investigated the effect of 
combination therapy with bevacizumab using DSC-MR imaging. We demonstrated that the inhibition 
of CCL2 blocked macrophage recruitment and angiogenesis, which resulted in decreased tumor volume 
and blood volume in CCL2-expressing GBM in a rat model. Our results provide direct evidence that CCL2 
expression can increase the resistance to bevacizumab, which can be assessed noninvasively with the 
DSC-MR imaging technique. This study shows that the suppression of CCL2 can play an important role 
in increasing the efficacy of anti-angiogenic treatment in GBM by inhibiting the recruitment of CCL2-
dependent macrophages.
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults, representing 
approximately 65% of all newly diagnosed malignant gliomas1. Even after aggressive therapies, including surgery, 
external-beam radiotherapy, and chemotherapy, GBM patients have an extremely poor outcome, with only 10% 
of patients surviving 5 years after the initial diagnosis2,3. These dismal survival statistics accentuate the immediate 
need for new approaches to treat GBM.
The antiangiogenic agent bevacizumab (Avastin) is a recombinant, humanized monoclonal antibody that 
directly targets vascular endothelial growth factor (VEGF) for the treatment of GBM4. Although bevacizumab, 
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alone or combined with other therapies, inhibits tumor angiogenesis and growth, GBM develops resistance to 
bevacizumab after an initial response to bevacizumab treatment. Eventually, GBM becomes progressively invasive 
with rapid growth5. One of the mechanisms of resistance to antiangiogenic therapy, in particular to bevacizumab, 
is associated with the myeloid cell infiltration of GBM6,7. The histological analysis of GBM revealed a heteroge-
neous cellular composition of neoplastic and nonneoplastic glioma cells, which form a tumor microenvironment 
comprising brain-resident microglia, infiltrating monocytes/macrophages, endothelial cells, pericytes, neural 
stem cells, and other immune cell infiltrates8,9. Monocytes/macrophages constitute up to 30% of the tumor mass 
in both human and murine GBM9,10. Moreover, increased tumor-associated macrophage (TAM) densities are 
correlated with shorter overall survival and with the vascular density within the tumor10,11. However, the mech-
anism by which TAMs affect the development of resistance against anti-angiogenic therapies in GBM remains 
largely obscure.
Chemokine (C-C motif) ligand 2 (CCL2) is one of the main chemoattractant for macrophages and has been 
implicated in glioma angiogenesis12,13. Macrophages that are recruited by CCL2 directly induce proangiogenic 
factors such as VEGF12,13. These recruited macrophages promote vascularization within tumors13,14. Together, 
these observations suggest that CCL2 is involved in tumor angiogenesis via macrophages. The modulation of 
CCL2-dependent macrophages in GBM has the potential to increase the treatment efficacy of anti-angiogenic 
agents such as bevacizumab. Thus, the CCL2-targeted Spiegelmer mNOX-E36 could be useful in this context.
Dynamic susceptibility contrast (DSC) perfusion MRI has been widely used as a diagnostic and prognos-
tic tool in the clinical setting. DSC-MRI can be used to determine the relative cerebral blood volume (rCBV) 
of the tumor, which has been shown to potentially predict the response to therapy in human GBM15. A high 
rCBV seems to indicate that a tumor is viable and is undergoing active neovascularization15. Consequently, this 
parameter has shown utility for characterizing histopathological features, differentiating brain abnormalities16, 
determining the prognosis of glioma patients17,18 based on the glioma grade15,18, confirming recurrence or pro-
gression17, predicting malignant transformation, and differentiating recurrent tumors from chemotherapy- or 
radiation-induced injury19. Therefore, DSC perfusion MRI is a suitable in vivo modality to assess the effects of 
CCL2-mediated TAM recruitment on the tumor vasculature in GBM.
Here, we showed that CCL2 expression resulted in enhanced tumor growth with increased resistance to bev-
acizumab in a rat GBM model. CCL2 inhibition by mNOX-E36 reduced the macrophage recruitment and was 
used as a combination therapy with bevacizumab. Subsequently, we observed that both the tumor size and blood 
volume decreased after combination therapy with mNOX-E36 and bevacizumab. Moreover, the positive correla-
tion between the CCL2 expression level and blood volume in GBM patients also suggests that CCL2 is a potential 
candidate for combination therapy with anti-angiogenic agents during GBM treatment. The purpose of this study 
was to assess the effects of CCL2 inhibition as a combination therapy with bevacizumab for the treatment of 
GBM, which was monitored with in vivo DSC perfusion MRI.
Results
CCL2 inhibition reduces macrophage migration without directly inhibiting angiogenesis in 
vitro. To analyze the effect of CCL2 inhibition, we used mNOX-E36 as a CCL2 inhibitor in CCL2-expressing 
tumor cells. We treated cells with varying concentrations of mNOX-E36 (0–400 µg/mL) for 24 hours, and no 
difference was observed between the untreated and treated groups at any dose (Supplementary Fig. S1). Further, 
the tumor cell viability was not changed during 72 hours of mNOX-E36 treatment (Fig. 1A). Decreased CCL2 
concentrations were observed at the intracellular level after treatment with mNOX-E36 [U87 MG; Vehicle vs. 
mNOX-E36 (p = 0.0041), LN 18; Vehicle vs. mNOX-E36 (p = 0.0001)] (Fig. 1B). The migration of macrophages 
among CCL2-expressing tumor cells decreased after mNOX-E36 (400 µg/mL) treatment compared to that of 
vehicle treatment [(U87 MG (p = 0.0075) and LN 18 (p = 0.0021)] (Fig. 2A,B). In the angiogenesis assay, the 
number of tubes generated by in vitro angiogenesis was not significantly different between the CCL2-expressing 
cells that were treated with mNOX-E36 and those that were treated with vehicle (p = 0.2492 in U87 MG and 
0.5309 in LN 18, respectively) (Fig. 2C,D). Our findings suggest that CCL2 inhibition by mNOX-E36 significantly 
decreases the macrophage migration to GBM cells without directly inhibiting angiogenesis.
Figure 1. (A) The viability of tumor cells was not affected by various incubation times (24 to 72 hours, n = 6) 
with mNOX-E36 (400 µg/mL) in either cell line. (B) Intracellular CCL2 expression (n = 5 in each group) was 
decreased in both U87 MG (p = 0.0041) and LN-18 (p = 0.0001) cells after mNOX-E36 treatment. PBS was used 
as a vehicle treatment (cell lysates were used for the measurement of intracellular levels).
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Coculture of CCL2-expressing tumor cells with macrophages promotes angiogenesis in vitro. 
To investigate the association of CCL2 expression with angiogenesis, we used an in vitro coculture model 
(Fig. 3A). In the coculture media of CCL2-expressing tumor cells with macrophages, the number of tubes that 
formed was significantly higher than that in the culture media from CCL2-expressing tumor cells only [U87 
MG; CCL2 vs. CCL2 with macrophages (p = 0.0040), LN 18; CCL2 vs. CCL2 with macrophages (p = 0.0017)] 
(Fig. 3B,C). This observation suggests that the interactions between the tumor cells and macrophages affects the 
secretion of CCL2, increasing angiogenesis and resulting in an enhanced number of tubes that form.
Antiangiogenic resistance increases with CCL2 expression and is suppressed by CCL2 inhibition 
in a rat GBM model. Next, we investigated the anticancer effect of combination therapy with bevacizumab 
and mNOX-E36 in a rat GBM model, which was monitored with DSC perfusion MRI. For this in vivo study, 
bevacizumab (20 mg/kg, twice/week) with or without mNOX-E36 (20 mg/kg, 4 times/week) was administered 
intraperitoneally to CCL2-expressing U87 MG tumor-bearing rats after undergoing a pretreatment MRI. A post-
treatment MRI was performed after 1 week (Fig. 4). Figure 5A shows representative anatomical T2WI and nCBV 
maps that were obtained in rats with mock tumors that were treated with bevacizumab and vehicle (left column, 
Mock-Vehicle) and in rats with CCL2-expressing tumors that were treated with bevacizumab and vehicle (middle 
column, CCL2-Vehicle) or bevacizumab and mNOX-E36 (right column, CCL2-mNOX-E36). Overall, the tumor 
volume increased on T2WI (Fig. 5B). However, in terms of the tumor volume ratio (%) and doubling time (DT), 
the CCL2-mNOX-E36 group had a significantly lower tumor volume ratio and a longer DT than those of the 
other two groups (Fig. 5C,D).
Furthermore, the change in the nCBV was assessed to monitor the therapeutic effects of the combination ther-
apy. In the Mock-Vehicle group, the posttreatment nCBV decreased compared with the pretreatment value after 
bevacizumab treatment, but the difference was not significant. However, in agreement with previous findings that 
showed an increase in tumor volume posttreatment, the nCBV was found to be increased in the CCL2-Vehicle 
group and to be decreased in the CCL2-mNOX-E36 group after treatment (Fig. 5E) compared to the respective 
tumor volumes before treatment. In terms of the nCBV ratio, the CCL2-Vehicle group had significantly higher 
values than those of the Mock-Vehicle group (p = 0.0002), and the CCL2-mNOX-E36 group demonstrated a 
significant decrease in the nCBV ratio compared with that of the CCL2-Vehicle group (p = 0.0012) (Fig. 5F). 
However, there were no significant differences in the nCBF, MTT, TTP and leakage ratios among the three groups 
(Supplementary Fig. S2).
Figure 2. (A) The macrophage migration toward mNOX-E36-treated cells was decreased (right) compared 
with the macrophage migration toward vehicle-treated cells (left) (upper: U87 MG, lower: LN 18). (B) Statistical 
analysis comparing the decrease of macrophage migration (%) toward both the CCL2-expressing U87 MG 
(p = 0.0075) and LN 18 (p = 0.0021) cells. (C,D) The angiogenesis assay showed no significant difference 
between vehicle-treated and mNOX-E36-treated CCL2-expressing tumor cells (U87 MG; p = 0.2492, LN 18; 
p = 0.5309). The number of tubes that formed during angiogenesis in vitro were measured.
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Infiltration of CCL2-dependent macrophages increases angiogenesis and tumor proliferation 
in vivo, which was suppressed after CCL2 inhibition in a rat GBM model. Furthermore, to examine 
the effect of combination therapy with mNOX-E36 and bevacizumab, histological analysis was performed (Fig. 6). 
We observed that CCL2 expression was significantly elevated in the CCL2-Vehicle group (Fig. 6A,B) compared 
to that in the Mock-Vehicle group. The number of the recruited macrophages was significantly increased in the 
CCL2-Vehicle group compared with that of the Mock-Vehicle group (p = 0.0154) and was correlated with the 
CCL2 expression (Fig. 6C and Supplementary Fig. S3). Moreover, the vascularity and tumor proliferation, as 
evaluated by CD34 (p = 0.0021) and KI-67 (p = 0.0451) staining, respectively, were higher in the CCL2-Vehicle 
group than in the Mock-Vehicle group (Fig. 6D,E). However, the tissue CCL2 levels were markedly decreased in 
the CCL2-mNOX-E36 group compared with those of the CCL2-Vehicle group (p = 0.0085) (Fig. 6A,B). Despite 
the maintained CCL2 expression, angiogenesis was decreased (p = 0.0026) and macrophage migration was lim-
ited (p = 0.0004) in the CCL2-mNOX-E36 group compared to those in the CCL2-Vehicle group. Moreover, the 
CCL2-mNOX-E36 group had a significantly lower KI-67 index compared with that of the CCL2-Vehicle group 
(p = 0.0129) (Fig. 6E). The number of necrotic cells, as measured by the release of the enzyme lactate dehydroge-
nase (LDH) and high-mobility group box 1 (HMGB1) levels, were significantly greater in the CCL2-mNOX-E36 
group than in the other groups [LDH: Mock-Vehicle vs. CCL2-mNOX-E36 (p < 0.0001), CCL2-Vehicle vs. 
CCL2-mNOX-E36 (p < 0.0001); HMGB1: Mock-Vehicle vs. CCL2-mNOX-E36 (p = 0.0007), CCL2-Vehicle 
vs. CCL2-mNOX-E36 (p = 0.0040)] (Supplementary Fig. S4). Furthermore, C57BL/6 J mice, an immunocom-
petent mouse model, showed significantly decreased CCL2 expression, F4/80, KI-67, and CD34 expression 
in CCL2-expressing tumors after mNOX-E36 treatment (Supplementary Fig. S5) compared to those of the 
CCL2-Vehicle group.
Long-term survival study in a mouse model with CCL2 expressing GBM. Mice with CCL2 
expressing GBM treated with Bev + mNOX-E36 (mean, 32.2 days ± 2.6) had longer survival than that with the 
Bev + Vehicle treatment (21.5 days ± 3.0; log-rank test, p = 0.0355) (Supplementary Fig. S6).
Positive correlations among the CCL2 expression, recruitment of macrophages, and nCBV in 
human GBM. Based on our preclinical in vivo results, we performed a correlation study to analyze the associ-
ation of CCL2-dependent macrophage recruitment with CBV in GBM patients (Table 1 and Fig. 7). CD68 mRNA 
expression, a marker for macrophages, was significantly correlated with CCL2 expression in GBM patients 
Figure 3. (A) The experimental design for the angiogenesis assay. (B) The number of tubes that formed is 
expressed as the angiogenic score, which showed that more angiogenesis occurred in the coculture media from 
CCL2-expressing tumor cells and macrophages than that from CCL2-expressing tumor cells only for both the 
(B) U87 MG (p = 0.0040) and (C) LN 18 (p = 0.0017) cells.
Figure 4. Timeline of the in vivo experiments. Abbreviations: DSC; dynamic susceptibility contrast.
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(r = 0.5170, p = 0.0068). In accordance with our in vivo animal data, both CCL2 (r = 0.5370, p = 0.0047) and 
CD68 mRNA expression (r = 0.6306, p = 0.0006) were significantly correlated with the nCBV as measured by 
DSC perfusion MRI. In addition, representative cases are also shown in Fig. 7E,F.
Discussion
In most brain tumors, macrophages and microglia are rich sources of stromal factors. Moreover, the fact that 
as many as 30–50% of the cells in gliomas are microglia or macrophages raises the intriguing possibility that 
targeting microglia and macrophages might represent an adjuvant therapeutic option for difficult-to-manage 
cancers20–23. The antiangiogenic agent bevacizumab, a recombinant humanized monoclonal antibody directed 
against VEGF, has been approved by the U.S. FDA for the treatment of GBM5,24. Although clinical trials with bev-
acizumab have shown benefits in regard to response and progression-free survival rates25,26, after anti-angiogenic 
therapy, GBM tumors often exhibit enhanced invasive and infiltrative phenotypes and inevitably relapse25,27. 
Together with these data, several studies have been performed to investigate tumor refractoriness after bevaci-
zumab treatment28,29. A recent study by Piao et al. showed that the survival of animals treated with bevacizumab 
in combination with sunitinib was increased compared with that of animals treated with only bevacizumab 
in an orthotopic mouse cancer model. Additionally, the combined treatment delayed macrophage infiltration 
until brain tumor progression30. Furthermore, Shojaei et al. reported that granulocyte colony-stimulating factor 
(G-CSF) was highly upregulated in refractory tumors of subcutaneously implanted mice28. In animals treated 
with anti-G-CSF, the circulation of tumor-associated myeloid cells was significantly reduced compared to that 
of untreated animals, demonstrating the important role of G-CSF in tumor refractoriness after bevacizumab 
treatment28. To date, many preclinical studies have indicated that bevacizumab alone does not induce prolonged 
tumor regression but does generate vessel normalization. Therefore, this treatment might still create a window of 
treatment opportunity for other agents.
The spiegelmer mNOX-E36, with CCL2-specific binding, is an interesting pharmacological modality because 
it is highly effective at low nanomolar concentrations, has favorable pharmacokinetic characteristics (based on 
efficient plasma levels at a once- or twice-weekly dosing schedule), and has no significant immunogenicity in 
vivo31–35. Hence, we considered mNOX-E36 to be well suited for the antagonism of CCL2 in the present study, 
Figure 5. The response of tumors to treatment was evaluated by T2WI and DSC perfusion MRI after 
combination therapy with mNOX-E36, a CCL2 inhibitor, and bevacizumab in U87 MG tumors. (A) T2WI 
shows the tumor boundaries (yellow arrow), and the nCBV maps obtained with perfusion MRI reveal the 
vascular changes in the tumors [left column: mock treated with bevacizumab only (Mock-Vehicle); middle 
column: CCL2-expressing tumor treated with bevacizumab and vehicle (CCL2-Vehicle); and right column: 
CCL2-expressing tumor treated with bevacizumab and mNOX-E36 (CCL2-mNOX-E36)]. (B) The tumor 
volume increased in all groups after treatment (black circle) compared with the pretreatment volume (white 
circle). (C) The tumor volume ratio (%) of the CCL2-mNOX-E36 group was significantly lower than that of 
the CCL2-Vehicle group (p = 0.0104). (D) The doubling time of the CCL2-mNOX-E36 group was significantly 
longer than that of the CCL2-Vehicle (p = 0.0143) group. (E) The nCBV of the CCL2-Vehicle group increased 
posttreatment (black circle) compared with the pretreatment nCBV (white circle), but the CCL2-mNOX-E36 
group showed decreased nCBV compared to the pretreatment nCBV. (F) The nCBV ratio (%) was significantly 
higher in the CCL2-Vehicle group than in Mock-Vehicle group (p = 0.0002) and in the CCL2-mNOX-E36 
group (p = 0.0012). Abbreviations: T2WI, T2 weighted imaging; DSC, dynamic susceptibility contrast; nCBV, 
normalized cerebral blood volume.
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Figure 6. Histological expression analysis of CCL2, CD68 (for macrophages), CD34 (for vascularity), and 
KI-67 (for cell proliferation) in each tumor (left column: Mock-Vehicle; middle column: CCL2-Vehicle and 
right column: CCL2-mNOX-E36). (A) Expression of all markers was higher in the CCL2-Vehicle group tumors 
than that in the tumors of the other groups. The first row shows that there was decreased CCL2 expression in 
the mNOX-E36-treated tumors, which also had a decrease in the recruitment of macrophages (second row), 
vascularity (third row), and cell proliferation (fourth row) (magnification: ×40). In the quantitative analysis, 
the CCL2-mNOX-E36 group also showed a further decrease in (B) the CCL2 level (p = 0.0085), (C) CD68 
positivity (p = 0.0004), (D) number of vessels (p = 0.0026) and (E) KI-67 index (p = 0.0129) in the tissue 
compared to those of the CCL2-Vehicle group. Abbreviations: FOV, field of view.
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and we used mNOX-E36 to investigate whether resistance to antiangiogenic treatment could be overcome with 
immunosuppressive therapy that blocked macrophage recruitment in GBM. CCL2 that is produced by the glioma 
microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells36. 
According to a study by Chang et al., elevated levels of CCL2 in clinical specimens of GBM correlated with the 
reduced overall survival of patients36. We believe that mNOX-E36 could be helpful for GBM patients with high 
CCL2 expression.
In our in vitro study, we established CCL2-expressing human GBM cell lines and demonstrated the ability of 
CCL2-expressing cells to promote angiogenesis via macrophage recruitment. We showed that macrophages did 
not migrate toward conditioned medium from CCL2-expressing cells after mNOX-E36 treatment. Moreover, 
our current study suggests that without macrophages, CCL2 expression cannot directly promote angiogenesis. 
Simultaneously, mNOX-E36, which does not directly affect tumor cell viability, also cannot inhibit angiogenesis. 
Interestingly, we observed that angiogenesis was increased when both CCL2-expressing cells and macrophages 
were cocultured to generate the conditioned medium. Based on these results, we hypothesized that the combi-
nation of CCL2 secretion of GBM and macrophage infiltration likely plays a critical role in promoting tumor 
angiogenesis, which encouraged us to perform in vivo studies.
In an in vivo study, bevacizumab (20 mg/kg, twice/a week) with or without mNOX-E36 (20 mg/kg, 4 times/a 
week) was administered intraperitoneally to CCL2-expressing U87 MG tumor-bearing rats after performing a 
pretreatment MRI. The experimental design for the in vivo study was based on our previous study, which showed 
bevacizumab resistance with the same U87 GBM nude rat model. In a previous study, we injected the bevaci-
zumab on the same days as in current study and assessed resistance by DSC perfusion MRI, without CCL2 inhibi-
tion treatment. Based on these results, we used bevacizumab before treating with a CCL2 inhibitor in the current 
study37. Furthermore, several studies have shown that bevacizumab does not work effectively alone, as men-
tioned in relationship to bevacizumab resistance and macrophage recruitment30,38,39. One recent study showed 
that reduced MIF expression was observed in bevacizumab-resistant glioma cells, which in turn was associated 
with increased M2-like TAM recruitment and the promotion of tumor progression and further resistance to 
anti-angiogenic treatment38. According to Lei Deng et al., an SDF-1 inhibitor could reverse the recruitment of 
macrophages, which in turn potentiated anti-VEGF treatment by bevacizumab and led to survival benefits39. In 
another study, Yuji Piao et al. characterized the change in tumor vasculature, cell proliferation and changes in 
the microenvironment, including the infiltration of different myeloid cell populations, which accounted for the 
differential outcomes observed with anti-VEGF treatment. The authors suggested that the ability to disrupt the 
recruitment of bone marrow-derived cells to gliomas is the most important mechanism for obtaining the benefi-
cial effects of anti-angiogenic therapies30.
Considering that our study was based on immunotherapy, we used histological analysis without DSC perfu-
sion MRI in an immunocompetent CCL2-expressing C57BL/6J GBM mouse model. According to previous stud-
ies, a C57BL/6J GBM mouse model that was generated with GL261 cells closely mimicked GBM phenotypes and 
was partially immunogenic, as the GL261 cells expressed high levels of MHC1. For this reason, recently, many 
researchers have preferred to use this model to perform immunotherapy-based research40–44. Unfortunately, the 
bolus injection of a contrast agent is difficult in mice due to their very small veins. However, the expression level 
of CCL2, proliferation, and vascularity in the C57BL/6J GBM mouse model were significantly decreased after 
mNOX-E36 treatment compared to those of the controls, and these results were consistent with those of the nude 
rat model, even though the MR study was not carried out (Supplementary Fig. S5).
Technically, several studies have reported that bioluminescence imaging (BLI) reveals slow tumor growth 
after anti-CCL2 treatment with docetaxel in mouse prostate cancer. However, the BLI photon counts over time 
showed no differences between the control and anti-CCL2-treated groups. As the error bars were relatively large, 
the inclusion of additional numbers of animals may allow for a more definitive conclusion to be drawn35. Another 
study by Rozel et al. using diffusion-weighted (DW)-MRI showed differential effects among docetaxel, anti-CCL2 
and a combination of docetaxel and anti-CCL2 treatments on PC3 tumor growth in a mouse bone tumor model. 
The authors reported that the diffusion measurements of the PC3 tumors increased over time based on the 
water apparent diffusion coefficient (ADC) values in response to both docetaxel and combined docetaxel and 
anti-CCL2. However, the DW-MRI results did not show that the anti-CCL2 treatment inhibited the infiltration of 
macrophages at the tumor site45. Our study may also be of interest for the development of future imaging strate-
gies for the management of patients who are undergoing GBM treatment. In this study, DSC perfusion MRI was 
Characteristics Total
No. of patients 26
Age (y)* 49.1 ± 13.33
Sex
  Male 19
  Female 7
CCL2 level* 55.98 ± 47.96
CD68 level* 84.07 ± 62.25
Tumor size (cm3)* 13.01 ± 9.66
mean nCBV* 4.90 ± 2.77
Table 1. Clinical characteristics of glioblastoma patients. *The data are shown as the mean ± standard 
deviation.
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used to monitor the anti-angiogenic effect due to the inhibition of the migration of CCL2-induced macrophages 
in bevacizumab-resistant GBM. DSC perfusion MRI allows the calculation of physiological parameters such as 
blood volume, blood-to-tissue transfer constant, and blood-brain-barrier integrity. In addition, this technique 
can be implemented to measure the size and density of the tumor vessels and offers additional important infor-
mation46–49. We evaluated the changes in vascularity, such as vessel density, rather than vascular permeability after 
each treatment, which can be evaluated by using DSC- and DCE-MRI, respectively30,50. Moreover, a decrease in 
Figure 7. Correlation analysis of the CD68 expression, CCL2 expression and nCBV in patients with GBM. 
GBM samples (n = 26) were analyzed. (A) qRT-PCR analysis revealed that the CD68 and CCL2 expression 
levels were positively correlated. (B) A scatter diagram and regression line display the positive correlation 
between the nCBV and CCL2 (r = 0.5370, p = 0.0047) or (C) CD68 expression levels (r = 0.6306, p = 0.0006). 
(D) A 3-dimensional graph of the nCBV, CCL2 and CD68. (E,F) MR imaging of representative patients who 
had low and high levels of CCL2 expression and the corresponding correlated nCBV values. Abbreviations: 
nCBV, normalized cerebral blood volume.
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tumor vascularity is known to be associated with bevacizumab treatment, which can be robustly correlated with 
pathologic findings. Therefore, DSC perfusion MRI is one of the best tools to analyze the antiangiogenic response 
related to the CCL2-induced recruitment of macrophages. Furthermore, it is important to establish a method that 
can allow continuous monitoring of the treatment response and/or recurrence in GBM patients using DSC per-
fusion MRI. An increased CBV value frequently suggests poor prognosis in GBM patients, which can be affected 
by several genetic and microenvironmental characteristics. Our animal and human studies showed that the CBV 
value in GBM is affected by macrophage recruitment, and the response to modulatory therapies can be monitored 
by DSC perfusion MR imaging.
However, there are several limitations in this study. First, bevacizumab sequesters only human (tumor-derived) 
VEGF. The previous studies showed that the mouse microenvironment could have secreted mouse VEGF in 
bevacizumab-treated animals and thus prevented excessive hypoxia, which was found to be associated with 
re-infiltration of macrophages30. Some evidence exists that the elimination of all VEGF from tumors may para-
doxically promote tumor growth51. We believe that a future study is warranted to determine the level of VEGF 
that is required for preventing or delaying this unwanted effect as well as to investigate the potential role of 
rodent VEGF on human cancer cells. Moreover, the concentration of bevacizumab used in this study to induce 
the bevacizumab resistance was determined according to our previous study37. However, the concentration was 
higher compared to the human dose. Second, we performed a survival analysis study to evaluate the benefit of 
mNOX-E36 in a CCL2-expressing tumor animal model, thus in future applications of our results, it will be helpful 
for selected candidates with high CCL2-expressing glioblastomas. Thus, we compared the survival of animals 
between the Bev + Vehicle and Bev + mNOX-E36 groups. In addition, we minimized the number of enrolled 
animals to comply with our institutional policy. Third, further clinical investigation is needed to validate our find-
ings. To date, mNOX-E36 has been evaluated in a phase II study in a patient with diabetic nephropathy, and it has 
not yet been approved for cancer patients52. We expect that, in the future, mNOX-E36 will be a relevant method 
to validate our therapeutic strategy of CCL2 inhibition in GBM patients.
In summary, this study shows that the suppression of CCL2 can play an important role in increasing the 
anti-angiogenic treatment efficacy in GBM by inhibiting the recruitment of CCL2-dependent macrophages 
in a rodent model, which was successfully monitored with DSC perfusion MRI. In addition, CCL2 expres-
sion is likely related to the aggressive nature of GBM, which may be crucial for selecting tailored treatment for 
CCL2-expressing GBM patients.
Materials and Methods
The in vivo study was approved by the institutional animal care and use committee of Seoul National University 
Hospital. Moreover, this retrospective human study was approved by the institutional review board of Seoul 
National University Hospital, and informed consent was waived. All research was performed in accordance with 
the relevant guidelines/regulations at our institute. Detailed methods are available in the online supplement.
Rat CCL2-expressing cell line. To establish a rat CCL2-expressing GBM cell line, rCCL2 (GenBank acces-
sion number NM_031530.1) cDNA was PCR amplified and cloned into a GenTarget lentiviral expression vector. 
The vector contains a GFP-Puromycin fusion dual marker under the control of the RSV promoter. The cloned 
insert was expressed under an enhanced constitutive CMV promoter (Supplementary Fig. S7). The primers for 
rCCL2 cDNA cloning were as follows:
rCCL2-F, 5′-AGCCTCCGGACTCTAGAGG-3′,
rCCL2-R, 5′-GCGGCATCAGAGCAGATTG-3′.
To express the rCCL2 transgene in cells, the U87 MG and LN 18 cell lines were transfected with lentivirus 
and were analyzed by fluorescence microscopy using green filters (Leica, Wetzlar, Germany). rCCL2 expression 
was confirmed by western blotting, immunocytochemistry, and cytokine assays (Supplementary Figs S8 and S9).
CCL2 antagonistic Spiegelmer mNOX-E36. The CCL2 binding Spiegelmer mNOX-E36 
(5′-GCGACAUUGGUUGGGCAUGAGGC-GAGGCCCUUUGAUGAAUCCGCGGCCA-3′) was modified 
at the 3′-terminus with 40-kDa polyethylene glycol and was synthesized at NOXXON Pharma AG (Berlin, 
Germany)36. In this study, mNOX-E36 was diluted in PBS for the in vitro studies and in 5% glucose for the in vivo 
studies.
Short-term in vivo treatment response study in a rat GBM model. We used 15 male athymic nude 
rats (6–8 weeks, Harlan) to generate an orthotopic brain tumor model using human GBM cell lines. Rats were 
anesthetized with a mixture of zolazepam and xylazine and were placed in a stereotaxic device. The U87 MG 
GBM cell line (3 × 106 cells/3 μl of serum-free RPMI) was inoculated into the right caudate-putamen region. 
Then, the in vivo MRI study was performed as shown in Fig. 1 and as described in a previous study34. Two weeks 
after cell implantation, the pretreatment T2-weighted imaging (T2WI) and DSC perfusion MRI were performed. 
Then, the GBM rats were divided into three groups (n = 5 in each group): a. Mock-Vehicle (mock U87 MG 
tumor treated with 20 mg/kg bevacizumab and 5% glucose (vehicle)); b. CCL2-Vehicle (CCL2-expressing U87 
MG tumor treated with 20 mg/kg bevacizumab and vehicle) and c. CCL2-mNOX-E36 (CCL2-expressing U87 
MG tumor treated with 20 mg/kg bevacizumab and 20 mg (based on oligonucleotide weight)/kg body weight 
mNOX-E36). mNOX-E36 and bevacizumab were injected intraperitoneally (i.p.) four times and two times, 
respectively, for one week37,53–56. The concentrations of bevacizumab40,57 and mNOX-E3658,59 used in this study 
were determined according to a previous study. Then, the brains were removed for histological analysis after the 
posttreatment DSC perfusion MR imaging acquisition.
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Long-term survival study in a mouse GBM model. For long-term survival analysis, we used 12 male 
nude mice (6–8 weeks) to generate an orthotopic brain tumor model using the CCL2-expressing U87 MG GBM 
cell line. Mice were anesthetized with a mixture of zolazepam and xylazine and were placed in a stereotaxic device. 
The U87 MG GBM cell line (106 cells/3 μl of serum-free RPMI) was inoculated into the right caudate-putamen 
region. Two weeks after cell implantation, a pretreatment MRI (only T2WI) was performed to confirm tumor 
growth. Then, the mice were divided into two groups (n = 6 in each group) according to tumor size, which was 
equally distributed between the two group: a. Bev + Vehicle (CCL2-expressing U87 MG tumor treated with 
20 mg/kg bevacizumab and vehicle) and b. Bev + mNOX-E36 (CCL2-expressing U87 MG tumor treated with 
20 mg/kg bevacizumab and 20 mg (based on oligonucleotide weight)/kg body weight mNOX-E36). mNOX-E36 
and bevacizumab were injected in the same manner as described above for the duration of the follow-up period. 
All mice were observed until euthanasia or the survival endpoint of 35 days.
Acquisition of patient samples. Tissue samples from 26 patients with histologically confirmed WHO 
grade IV glioblastoma were obtained during surgery. The patients underwent gross total resection followed by 
concurrent chemoradiotherapy with temozolomide and adjuvant temozolomide for six cycles. All tumor samples 
used in this study were snap-frozen in liquid nitrogen as soon as possible during the surgery and were stored 
at − 80 °C. Histological diagnosis was performed using the criteria described in the 2007 WHO Classification of 
Tumors of the Central Nervous System60. Mutations in patient samples were detected via targeted sequencing, as 
described previously61.
Image postprocessing and data analysis. DSC perfusion MR images were processed by using commer-
cial software (Nordic ICE and NordicNeuroLab, respectively), in which the CE-T1WI or T2WI were used for 
structural imaging. The rCBV maps were generated using established tracer kinetic models that were applied to 
the first-pass data16. To reduce the recirculation effects, the ΔR2* (1/T2*) curves were fitted to a gamma-variate 
function, which is an approximation of the first pass response as it would appear in the absence of recirculation 
or leakage. We did not use an arterial input function in the perfusion analysis. The dynamic curves were mathe-
matically corrected to reduce the contrast-agent leakage effects. Normalization of rCBV maps was automatically 
performed using the mean value of the blood volume values outside of the tumor, without any intervention of the 
observers while making the normalized rCBV (nCBV) maps. Then, the normalized cerebral blood flow (nCBF), 
mean transit time (MTT), time-to-peak (TTP), and leakage maps were generated for the rat DSC perfusion MR 
images. The nCBV, nCBF, MTT, TTP, and leakage maps are presented as color overlays on structural images.
One investigator (S.H.C., 14 years of experience in neuroradiology) who was blinded to the experimental or 
clinical data drew ROIs that contained the entire tumor on every continuous section of the coregistered images. 
Tumor boundaries were defined with reference to the high-signal intensity areas that were thought to represent 
tumor tissue on the T2WI. Areas of necrosis, hemorrhage, or macrovessels were first identified in the conven-
tional MR imaging sequences and were excluded carefully from the ROIs. After obtaining the total voxel values 
of the nCBV of each tumor, the total volume and mean nCBV of each tumor were calculated. In the rat model, 
the tumor doubling time (DT), measured in days, was calculated by using the following equation: DT = t × log2/
(logV − logV0), where t is the time between the two measurements and V0 and V denote the tumor volume at 
the initial and last MRI examinations, respectively62. Additionally, the tumor volume, nCBV, nCBF, MTT and 
TTP ratios (posttreatment value/pretreatment value × 100) were also calculated. Tumors with negative DTs were 
excluded from the DT comparison study among the groups.
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files)
References
 1. Dolecek, T. A., Propp, J. M., Stroup, N. E. & Kruchko, C. CBTRUS Statistical Report: Primary Brain and Central Nervous System 
Tumors Diagnosed in the United States in 20052009. Neuro-Oncology 14, v1–v49, https://doi.org/10.1093/neuonc/nos218 (2012).
 2. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in 
glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 10, 459–466, https://doi.
org/10.1016/S1470-2045(09)70025-7 (2009).
 3. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987–996, https://doi.
org/10.1056/NEJMoa043330 (2005).
 4. Norden, A. D. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 
779–787, https://doi.org/10.1212/01.wnl.0000304121.57857.38 (2008).
 5. Piao, Y. et al. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant 
glioblastoma mouse models. Neuro Oncol 18, 1230–1241, https://doi.org/10.1093/neuonc/now030 (2016).
 6. Peterson, T. E. et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in 
glioblastoma by altering macrophages. Proc Natl Acad Sci USA 113, 4470–4475, https://doi.org/10.1073/pnas.1525349113 (2016).
 7. De Palma, M. & Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277–286, https://
doi.org/10.1016/j.ccr.2013.02.013 (2013).
 8. Becher, O. J. et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 68, 
2241–2249, https://doi.org/10.1158/0008-5472.CAN-07-6350 (2008).
 9. Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R. & Kettenmann, H. The brain tumor microenvironment. Glia 60, 502–514 
(2012).
 10. Hambardzumyan, D., Gutmann, D. H. & Kettenmann, H. The role of microglia and macrophages in glioma maintenance and 
progression. Nat Neurosci 19, 20–27, https://doi.org/10.1038/nn.4185 (2016).
 11. Bowman, R. L. & Joyce, J. A. Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. Immunotherapy 
6, 663–666, https://doi.org/10.2217/imt.14.48 (2014).
 12. Chanmee, T., Ontong, P., Konno, K. & Itano, N. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. 
Cancers 6, 1670–1690, https://doi.org/10.3390/cancers6031670 (2014).
1 1Scientific RepoRtS |         (2019) 9:11085  | https://doi.org/10.1038/s41598-019-47438-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 13. Low-Marchelli, J. M. et al. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res 73, 662–671, https://
doi.org/10.1158/0008-5472.CAN-12-0653 (2013).
 14. Arendt, L. M. et al. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res 73, 
6080–6093, https://doi.org/10.1158/0008-5472.CAN-13-0926 (2013).
 15. Law, M. et al. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-
weighted contrast-enhanced perfusion MR imaging. Radiology 247, 490–498, https://doi.org/10.1148/radiol.2472070898 (2008).
 16. Rollin, N. et al. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors. 
Neuroradiology 48, 150–159, https://doi.org/10.1007/s00234-005-0030-7 (2006).
 17. Danchaivijitr, N. et al. Low-grade gliomas: Do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging 
predict malignant transformation? Radiology 247, 170–178, https://doi.org/10.1148/radiol.2471062089 (2008).
 18. Sugahara, T. et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic 
determination of vascularity of gliomas. Am J Roentgenol 171, 1479–1486, https://doi.org/10.2214/ajr.171.6.9843274 (1998).
 19. Barajas, R. F. et al. Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation 
Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging. Radiology 253, 486–496, https://doi.
org/10.1148/radiol.2532090007 (2009).
 20. Gutmann, D. H. et al. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. 
Genome Res 23, 431–439, https://doi.org/10.1101/gr.142604.112 (2013).
 21. Simmons, G. W. et al. Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to 
mouse optic glioma formation and growth. J Neuropathol Exp Neurol 70, 51–62, https://doi.org/10.1097/NEN.0b013e3182032d37 (2011).
 22. Morantz, R. A., Wood, G. W., Foster, M., Clark, M. & Gollahon, K. Macrophages in experimental and human brain tumors. Part 2: 
studies of the macrophage content of human brain tumors. J Neurosurg 50, 305–311, https://doi.org/10.3171/jns.1979.50.3.0305 
(1979).
 23. Rossi, M. L., Hughes, J. T., Esiri, M. M., Coakham, H. B. & Brownell, D. B. Immunohistological Study of Mononuclear Cell Infiltrate 
in Malignant Gliomas. Acta Neuropathol 74, 269–277, https://doi.org/10.1007/Bf00688191 (1987).
 24. Kim, M. M., Umemura, Y. & Leung, D. Bevacizumab and Glioblastoma Past, Present, and Future Directions. Cancer J 24, 180–186, 
https://doi.org/10.1097/Ppo.0000000000000326 (2018).
 25. Chinot, O. L. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. Expert Rev Anticanc 
12, 1413–1427, https://doi.org/10.1586/Era.12.128 (2012).
 26. Sorensen, A. G. et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood 
perfusion. Cancer Res 72, 402–407, https://doi.org/10.1158/0008-5472.CAN-11-2464 (2012).
 27. Lucio-Eterovic, A. K., Piao, Y. & de Groot, J. F. Mediators of glioblastoma resistance and invasion during antivascular endothelial 
growth factor therapy. Clin Cancer Res 15, 4589–4599, https://doi.org/10.1158/1078-0432.CCR-09-0575 (2009).
 28. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells. Nat Biotechnol 25, 
911–920, https://doi.org/10.1038/nbt1323 (2007).
 29. Boer, J. C., Walenkamp, A. M. & den Dunnen, W. F. Recruitment of bone marrow derived cells during anti-angiogenic therapy in 
GBM: the potential of combination strategies. Crit Rev Oncol Hematol 92, 38–48, https://doi.org/10.1016/j.critrevonc.2014.05.001 
(2014).
 30. Piao, Y. J. et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and 
a mesenchymal phenotype. Neuro-Oncology 14, 1379–1392, https://doi.org/10.1093/neuonc/nos158 (2012).
 31. Kulkarni, O. et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 18, 
2350–2358, https://doi.org/10.1681/Asn.2006121348 (2007).
 32. Wlotzka, B. et al. In vivo properties of an anti-GnRH Spiegelmer: An example of an oligonucleotide-based therapeutic substance 
class. P Natl Acad Sci USA 99, 8898–8902, https://doi.org/10.1073/pnas.132067399 (2002).
 33. Kulkarni, O. et al. Anti-Ccl2 Spiegelmer Permits 75% Dose Reduction of Cyclophosphamide to Control Diffuse Proliferative Lupus 
Nephritis and Pneumonitis in MRL-Fas(lpr) Mice. J Pharmacol Exp Ther 328, 371–377, https://doi.org/10.1124/jpet.108.142711 
(2009).
 34. Ninichuk, V. et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves 
glomerular filtration rate in db/db mice. Am J Pathol 172, 628–637, https://doi.org/10.2353/ajpath.2008.070601 (2008).
 35. Loberg, R. D. et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in 
vivo. Cancer Res 67, 9417–9424, https://doi.org/10.1158/0008-5472.Can-07-1286 (2007).
 36. Chang, A. L. et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and 
Myeloid-Derived Suppressor Cells. Cancer Res 76, 5671–5682, https://doi.org/10.1158/0008-5472.Can-16-0144 (2016).
 37. Cho, H. R. et al. Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: 
application of DSC perfusion MR imaging. Oncotarget 7, 69606–69615, https://doi.org/10.18632/oncotarget.11901 (2016).
 38. Castro, B. A. et al. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic 
therapy. Oncogene 36, 3749–3759, https://doi.org/10.1038/onc.2017.1 (2017).
 39. Deng, L. et al. SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI. Neoplasia 19, 1–7, 
https://doi.org/10.1016/j.neo.2016.11.010 (2017).
 40. Yun, T. J. et al. Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat 
Glioblastoma Model. Am J Neuroradiol 37, 1650–1656, https://doi.org/10.3174/ajnr.A4800 (2016).
 41. Oh, T. et al. Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med 12, https://doi.
org/10710.1186/1479-5876-12-107 (2014).
 42. Szulzewsky, F. et al. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization 
and highly express Gpnmb and Spp1. Plos One 10, e0116644, https://doi.org/10.1371/journal.pone.0116644 (2015).
 43. Hung, A. L. et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology 
7, e1466769, https://doi.org/10.1080/2162402X.2018.1466769 (2018).
 44. Kim, J. E. et al. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. 
Clin Cancer Res 23, 124–136, https://doi.org/10.1158/1078-0432.CCR-15-1535 (2017).
 45. Rozel, S. et al. Synergy Between anti-CCL2 and Docetaxel as Determined by DW-MRI in a Metastatic Bone Cancer Model. J Cell 
Biochem 107, 58–64, https://doi.org/10.1002/jcb.22056 (2009).
 46. Emblem, K. E. et al. Vessel calibre-a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol 11, 566–584, 
https://doi.org/10.1038/nrclinonc.2014.126 (2014).
 47. O’Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C. & Jayson, G. C. Dynamic contrast-enhanced MRI in clinical trials of 
antivascular therapies. Nat Rev Clin Oncol 9, 167–177, https://doi.org/10.1038/nrclinonc.2012.2 (2012).
 48. Viel, T. et al. Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal 
PET and MRI. Eur J Nucl Med Mol I 40, 1595–1606, https://doi.org/10.1007/s00259-013-2464-1 (2013).
 49. Kalpathy-Cranner, J., Gerstner, E. R., Emblen, K. E., Andronesi, O. C. & Rosen, B. Advanced Magnetic Resonance Imaging of the 
Physical Processes in Human Glioblastoma. Cancer Res 74, 4622–4637, https://doi.org/10.1158/0008-5472.Can-14-0383 (2014).
 50. Zhang, J. et al. Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current 
Challenges. Contrast Media Mol Imaging 2017, 7064120, https://doi.org/10.1155/2017/7064120 (2017).
1 2Scientific RepoRtS |         (2019) 9:11085  | https://doi.org/10.1038/s41598-019-47438-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
 51. Vecchiarelli-Federico, L. M. et al. Vascular Endothelial Growth Factor-A Positive and Negative Regulator of Tumor Growth. Cancer 
Res 70, 863–867, https://doi.org/10.1158/0008-5472.Can-09-3592 (2010).
 52. Menne, J. et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. 
Nephrol Dial Transpl 32, 307–315, https://doi.org/10.1093/ndt/gfv459 (2017).
 53. Demeure, K. et al. Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM). Mol 
Cell Proteomics 15, 481–492, https://doi.org/10.1074/mcp.M115.052423 (2016).
 54. Grossman, R. et al. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. J Neurooncol 
116, 59–65, https://doi.org/10.1007/s11060-013-1268-2 (2014).
 55. Grossman, R. et al. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother 
Pharmacol 70, 129–139, https://doi.org/10.1007/s00280-012-1867-1 (2012).
 56. Keunen, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci 
USA 108, 3749–3754, https://doi.org/10.1073/pnas.1014480108 (2011).
 57. von Baumgarten, L. et al. Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells. 
Clinical Cancer Research 17, 6192–6205, https://doi.org/10.1158/1078-0432.Ccr-10-1868 (2011).
 58. Baeck, C. et al. Pharmacological Inhibition of the Chemokine C-C Motif Chemokine Ligand 2 (Monocyte Chemoattractant Protein 
1) Accelerates Liver Fibrosis Regression by Suppressing Ly-6C(+) Macrophage Infiltration in Mice. Hepatology 59, 1060–1072, 
https://doi.org/10.1002/hep.26783 (2014).
 59. Ehling, J. et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 63, 1960–1971, 
https://doi.org/10.1136/gutjnl-2013-306294 (2014).
 60. Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97–109, https://doi.
org/10.1007/s00401-007-0243-4 (2007).
 61. Myung, J. K. et al. IDH1 mutation of gliomas with long-term survival analysis. Oncol Rep 28, 1639–1644, https://doi.org/10.3892/
or.2012.1994 (2012).
 62. Ozono, S. et al. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn 
J Clin Oncol 34, 82–85 (2004).
Acknowledgements
The project was supported by the Brain Research Program through the National Research Foundation of 
Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (2016 M3C7A1914002), by grant no 
0320160100 (2016-1087) from the SNUH Research Fund, by the Creative-Pioneering Researchers Program 
through Seoul National University (SNU), and by Project Code (IBS-R006-D1).
Author Contributions
H.R.C., H.K., H.T.V., N.K., C.-K.P. and S.H.C. conceived the study. H.R.C. and S.H.C. wrote the main manuscript 
text. H.R.C., H.J., N.K. and S.H.C. conducted the experiments. H.R.C., H.K. and C.-K.P. analyzed the results. All 
authors reviewed the manuscript.
Additional information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47438-4.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
